Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain; Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (i+12), 28041 Madrid, Spain.
Molecular Immunology Unit, Hospital Universitario Puerta de Hierro Majadahonda, 2822 Majadahonda, Madrid, Spain.
Trends Immunol. 2019 Mar;40(3):243-257. doi: 10.1016/j.it.2019.01.008.
The redirection of T cell activity towards cancer cells via targeting of tumor-associated antigens (TAAs) by soluble bispecific antibodies (bsAbs) or membrane-anchored chimeric antigen receptors is one of the most promising cancer immunotherapy strategies currently in development. We review here an emerging approach that combines aspects of antibody- and cell-based therapies: STAb immunotherapy, based on the endogenous secretion of T cell-redirecting bsAbs (STAb). STAb immunotherapies use ex vivo or in vivo genetic modifications of different cell types with nucleic acids or viral vectors encoding bsAbs; these can result in effective and persistent concentrations of antibodies. After introducing core concepts, we discuss plausible ways by which STAb strategies might be further developed to improve their potential efficacy and safety in preclinical and clinical testing.
通过针对肿瘤相关抗原 (TAA) 的可溶性双特异性抗体 (bsAb) 或膜锚定嵌合抗原受体将 T 细胞活性重定向至癌细胞是目前正在开发的最有前途的癌症免疫治疗策略之一。在这里，我们回顾了一种新兴的方法，该方法结合了抗体和细胞治疗的各个方面：基于内源性分泌 T 细胞重定向 bsAb（STAb）的 STAb 免疫疗法。STAb 免疫疗法使用核酸或编码 bsAb 的病毒载体对不同类型的细胞进行体外或体内基因修饰；这可以导致有效的和持久的抗体浓度。在介绍核心概念之后，我们讨论了可能的方式，通过这些方式，STAb 策略可以进一步发展，以提高其在临床前和临床试验中的潜在疗效和安全性。
